VANCOUVER, British Columbia, Jan. 22, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV), a biopharmaceutical company at the forefront of AI-driven drug discovery, yesterday commented on the announcement of a $500 billion private-sector investment into AI infrastructure by OpenAI, SoftBank, and Oracle through their joint venture, Stargate. This historic initiative marks a defining moment for the AI and healthcare sectors, setting the stage for transformative advancements in precision medicine and drug discovery.
Pioneering AI Applications in Healthcare
The Stargate initiative will see the construction of 20 advanced AI data centers, delivering the massive computational capacity needed to fuel breakthroughs across industries, including healthcare. By enabling faster and more robust data analysis, this infrastructure will play a crucial role in advancing drug discovery, personalized medicine, and healthcare delivery.
"This announcement is a milestone for the AI industry and underscores the enormous potential for artificial intelligence to transform healthcare,” said Jeffrey Bacha, Executive Chairman of Rakovina Therapeutics. "As innovators leveraging AI in oncology, we see this as an exciting opportunity to align with the industry's forward momentum and accelerate the discovery of new cancer therapies.”
Strategically Positioned for Growth
Rakovina Therapeutics has already integrated cutting-edge AI platforms, such as Deep Docking™ and Enki™, into its drug discovery programs. These technologies enable the company to analyze billions of molecular interactions and identify promising candidates targeting DNA-damage response pathways in cancer. As the global AI ecosystem expands, initiatives like Stargate are expected to amplify Rakovina's ability to:
- Leverage Enhanced AI Infrastructure: Increased computational power will further streamline and optimize drug candidate discovery, reducing time and costs associated with development.
- Drive Innovation in Precision Medicine: AI advancements will enhance Rakovina's ability to target specific cancer vulnerabilities with highly effective therapies.
- Explore New Collaboration Opportunities: The growing focus on AI-driven healthcare solutions creates avenues to engage with leading organizations shaping this space.
- Deliver Shareholder Value: By staying at the forefront of AI innovation, Rakovina is well-positioned to drive value through accelerated research and expanded market opportunities.
Rakovina is committed to advancing its pipeline of DNA-damage response inhibitors through AI-powered discovery and preclinical validation. These advancements not only hold the potential to transform cancer treatment but also highlight the company's ability to capitalize on sector-wide investments in AI infrastructure.
"AI is redefining what's possible in medicine, and the establishment of new AI infrastructure will have ripple effects across the entire healthcare sector,” added Bacha. "We're excited to continue advancing our mission to bring innovative therapies to patients and drive value for our shareholders.”
About Rakovina Therapeutics Inc.
Rakovina Therapeutics is a biopharmaceutical research company focused on the development of innovative cancer treatments. By leveraging advanced AI platforms alongside traditional research, Rakovina aims to significantly reduce the time and cost associated with drug discovery, targeting DNA-damage response vulnerabilities in tumors. The company's goal is to advance one or more drug candidates into human clinical trials in collaboration with pharmaceutical partners. Further information may be found at www.rakovinatherapeutics.com.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSXV) accepts responsibility for the adequacy or accuracy of this release.
Forward-Looking Statements
This release includes forward-looking statements regarding the Company and its respective business, which may include, but is not limited to, statements with respect to the proposed business plan of the Company and other statements. Often, but not always, forward-looking statements can be identified by the use of words such as "plans”, "is expected”, "expects”, "scheduled”, "intends”, "contemplates”, "anticipates”, "believes”, "proposes” or variations (including negative variations) of such words and phrases, or state that certain actions, events, or results "may”, "could”, "would”, "might” or "will” be taken, occur or be achieved. Such statements are based on the current expectations of the management of the Company. The forward-looking events and circumstances discussed in this release may not occur by certain specified dates or at all and could differ materially as a result of known and unknown risk factors and uncertainties affecting the Company, including risks regarding the medical device industry, economic factors, regulatory factors, the equity markets generally and risks associated with growth and competition.
Although the Company has attempted to identify important factors that could cause actual actions, events, or results to differ materially from those described in forward-looking statements, there may be other factors that cause actions, events, or results to differ from those anticipated, estimated or intended. No forward-looking statement can be guaranteed. Except as required by applicable securities laws, forward-looking statements speak only as of the date on which they are made and the Company undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise. The reader is referred to the Company's most recent filings on SEDAR+ for a more complete discussion of all applicable risk factors and their potential effects, copies of which may be accessed through the Company's profile page at www.sedarplus.ca.
Investor Relations and Media:
Michelle Seltenrich, BSc MBA
Director, Corporate Development
778-773-5432
